Solving the Complexities of T Cell Engager Development

T-cell engagers (TCEs) are a class of bispecific antibodies that simultaneously bind tumor cells and T cells, activating T cells and mediating their cytotoxic effects on tumor cells. However, their complex structure and mechanism of action demand a rigorous understanding of pharmacology, safety, and translational biology.

In this webinar, WuXi AppTec scientists discuss pharmacological approaches for TCEs, including predictive biomarker detection and the use of diverse humanized preclinical models and knock-in systems that recapitulate the immune-tumor microenvironment. Our specialists also address the bioanalytical complexities inherent to TCE therapeutics, including critical considerations in pharmacokinetic profiling and immunogenicity assessment.

← Return to Resources

Related Content

Bispecific antibodies have emerged as an important modality in oncology, although their broader application can be limited by manufacturing complexity...

VIEW RESOURCE

As PD-1/PD-L1 x VEGF-targeted bispecific antibodies gain momentum in oncology, selecting the right preclinical models is becoming increasingly important. These...

VIEW RESOURCE
← View all Antibodies Resources
× peptide, amino acid

Contact An Expert Today!